A Phase IIa Study to Build an Understanding of the Pharmacokinetic-Pharmacodynamic Relationship of PSN821 in Type 2 Diabetes Patients (T2DM).
Phase of Trial: Phase I/II
Latest Information Update: 16 Aug 2012
At a glance
- Drugs PSN 821 (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 16 Aug 2012 Actual end date (May 2012) added as reported by ClinicalTrials.gov.
- 11 Oct 2011 Planned end date changed from 1 Dec 2011 to 1 Jun 2012 as reported by ClinicalTrials.gov.
- 11 Oct 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.